Matching Therapy to Substrate
The final chapter. Every rhythm has a mechanism. Every mechanism implies a therapy. This is where the whole story converges.
If you understand the mechanism, the treatment follows logically. That has been the thesis of this entire project.
We began with ion channels and a resting membrane potential. From there we built upward: the action potential, refractory periods, gap junctions, the conduction system, and the failure modes that produce arrhythmias. Reentry, triggered activity, and enhanced automaticity each generate specific rhythms. The EP lab techniques in Volume VI prove which mechanism is operating in a given patient.
Volume VII showed how drugs reshape the electrical substrate, current by current, and why the same drug can cure one rhythm and worsen another. The preceding chapters of this volume asked when ablation, devices, or observation is the right answer. This final chapter pulls it all together.
Three Mechanisms, Three Therapeutic Logics
Every sustained arrhythmia falls into one of three mechanistic categories. Each category responds to a different therapeutic approach, and the mismatch between mechanism and therapy explains most treatment failures.
Reentry
Circuit-dependent | Most common clinical mechanism
The wavefront travels in a loop. It requires a circuit with an excitable gap: tissue ahead of the wavefront that has recovered and can be depolarized again. The circuit continues as long as the gap exists.
Therapeutic logic: interrupt the circuit. This can be done three ways:
- Ablation: destroy the critical isthmus (CTI flutter, AVNRT slow pathway, scar VT channel, accessory pathway).
- Drugs: slow conduction or extend refractoriness enough that the wavefront catches up to its own refractory tail and extinguishes (sodium blockers slow the wavefront; potassium blockers extend refractoriness).
- Pacing/Shock: overdrive pacing captures the excitable gap and terminates the circuit (ATP from an ICD); defibrillation resets all tissue simultaneously.
AVNRT, AVRT, typical atrial flutter, scar VT, most monomorphic VT, bundle branch reentry VT
Triggered Activity
Afterdepolarization-dependent | Calcium-driven
The cell fires abnormally because calcium overload causes afterdepolarizations, early (EADs, during phase 2-3) or delayed (DADs, during phase 4). Each afterdepolarization that reaches threshold triggers another beat.
Therapeutic logic: eliminate the trigger or suppress the calcium overload.
- Ablation: effective when the trigger comes from a focal source (outflow tract VT, some PV-triggered atrial tachycardia).
- Drugs: beta-blockers reduce cAMP and calcium loading. Calcium channel blockers directly limit the current. Adenosine crushes cAMP-dependent triggered activity.
- Correct the cause: stop digoxin (DADs), correct hypokalemia/hypomagnesemia (EADs), treat ischemia.
Outflow tract VT/PVCs, digoxin-toxic rhythms, catecholaminergic polymorphic VT (CPVT), some focal ATs, Torsades de Pointes (EAD-driven)
Enhanced Automaticity
Intrinsic rate acceleration | Phase 4 slope
Cells that normally depolarize slowly (or shouldn't depolarize at all) begin firing faster than the sinus node. The phase 4 slope steepens, threshold is reached sooner, and the ectopic focus takes over the rhythm.
Therapeutic logic: suppress the ectopic focus or address the underlying driver.
- Ablation: effective when the focus is discrete and mappable (some automatic ATs, parasystolic foci).
- Drugs: beta-blockers reduce sympathetic drive that steepens phase 4. Calcium channel blockers slow nodal automaticity.
- Correct the cause: treat hyperthyroidism, sepsis, hypoxia, electrolyte derangements. Once the metabolic driver is removed, the automaticity resolves.
Automatic atrial tachycardia, accelerated idioventricular rhythm (AIVR), junctional ectopic tachycardia, inappropriate sinus tachycardia, parasystole
The Framework in Action
To show how this works in practice, consider four patients who arrive in the EP lab. Each has a different arrhythmia, a different mechanism, and a different optimal therapy, all traceable back to the principles covered across these eight volumes.
Case 1
28-year-old with palpitations and a delta wave
Mechanism: Reentry via an accessory pathway (AVRT). The circuit uses the AV node as the antegrade limb and the pathway as the retrograde limb. The pathway crosses the AV groove at a single anatomical point.
Why ablation: The circuit has an obligate bottleneck, the accessory pathway insertion point. Destroying that point eliminates the retrograde limb. The circuit can never form again. Success rate >95%, curative.
Why not drugs: AV nodal blockers can slow the circuit acutely, but the pathway persists. The patient faces lifelong medication with side effects for a problem that can be cured in one procedure.
Case 2
65-year-old with ischemic cardiomyopathy and recurrent VT
Mechanism: Scar-related reentry. The old infarct scar contains surviving muscle bundles that form reentrant circuits. Multiple circuits may coexist within the same scar.
Why ICD + ablation + drugs: The ICD is the safety net. It terminates any VT/VF episode within seconds, preventing sudden death. Ablation targets the dominant circuit's critical isthmus to reduce VT frequency. Amiodarone or sotalol suppresses triggers and slows circuits. All three are needed because the substrate is extensive and cannot be fully eliminated.
Why not ablation alone: The scar harbors multiple potential circuits. Eliminating one may unmask another. Ablation reduces burden but cannot guarantee that VF will never occur in this substrate.
Case 3
45-year-old with repetitive monomorphic PVCs from the RVOT
Mechanism: Triggered activity (cAMP-mediated DADs) from a small nest of cells in the right ventricular outflow tract. Structurally normal heart.
If burden is low (<10%) and asymptomatic: Observe. The normal heart has no substrate for lethal reentry. The PVCs are annoying but harmless at this burden.
If burden is high (>15%) or EF declining: Ablation. The source is focal, mappable, and far from the His bundle. One lesion eliminates the focus. The cardiomyopathy reverses. Alternatively, beta-blockers can suppress the triggered activity by reducing cAMP.
Case 4
72-year-old with syncope and Mobitz II block
Mechanism: Infra-Hisian conduction failure. Fibrosis has destroyed part of the bundle branch system. Conduction intermittently fails, causing dropped QRS complexes. The block is below the His bundle, which means it's structural and progressive.
Why pacemaker: The conduction tissue is degenerating. No drug regenerates it. There is nothing to ablate; the tissue itself is gone. A dual-chamber pacemaker ensures that every atrial impulse is followed by a ventricular contraction, preventing syncope and sudden death from prolonged asystole.
Why not drugs: Atropine and isoproterenol can transiently improve AV nodal conduction, but the block is below the node. These drugs don't reach the His-Purkinje system in a meaningful way. The fibrosis is permanent.
The End of the Story
This has been a story about electricity in the human heart, told from the inside out, from ion to organ, from cell to cath lab.
The central lesson is that the mechanism explains everything. Why a drug works. Why it fails. Why ablation cures one rhythm instantly and barely dents another. Why some patients need hardware sewn into their chest, and why others need nothing more than reassurance. The diagnosis is a label. The mechanism is the understanding.
When you sit in the EP lab and watch an intracardiac electrogram scroll across the screen, you're watching the story of ion channels and gap junctions, refractory periods and wavefronts, playing out in real time inside a living heart. Every signal has a physical explanation. Every therapy has a mechanistic rationale.
That's the heart's electrical story. And now you know how to read it.
How the EP Lab Tests It
The proof that a rhythm is reentry, triggered, or automatic comes before we choose any therapy, and it comes from how the rhythm behaves under programmed stimulation. We thread catheters into the heart and deliver a drive train of paced beats followed by a single premature extrastimulus, and we watch what the tissue does. Reentry announces itself: a critically timed extrastimulus, one landing inside the excitable gap, starts and stops the tachycardia reproducibly. A rhythm that pacing can neither initiate nor terminate is not living in a fixed circuit.
Once reentry is running, entrainment localizes the target. We pace from inside the suspected circuit slightly faster than the tachycardia, and when the surface QRS shows concealed fusion (paced beats identical to the spontaneous ones) with a post-pacing interval matching the tachycardia cycle length, the catheter is sitting in the protected isthmus. That is the ablation lesion set, confirmed physiologically before we burn. For the narrow-complex SVT, a bolus of adenosine that blocks the AV node terminates the AV-nodal-dependent circuit, separating it from atrial rhythms that conduct through unaffected.
Triggered activity and automaticity often stay silent under pacing alone, so we infuse isoproterenol to raise catecholamine tone and cAMP. Outflow-tract triggered activity and catecholamine-sensitive automatic foci emerge on isoproterenol and can then be mapped to their earliest site, while beta-blockade or adenosine suppresses them. Each response points to one mechanism, and the mechanism points to one therapy: ablate the fixed circuit, suppress the trigger, or leave the benign focus alone.
Key Takeaways
- Reentrant rhythms are treated by interrupting the circuit: ablation for discrete isthmuses, drugs to close the excitable gap, pacing/shock to capture or reset the circuit.
- Triggered rhythms respond to calcium management (beta-blockers, CCBs, adenosine) and ablation of the focal source. Correcting the underlying cause (toxicity, electrolytes) is often the definitive therapy.
- Automatic rhythms are best managed by treating the underlying metabolic driver. Ablation works when the focus is discrete and persistent.
- Conduction failure (block, SND) requires hardware. The tissue is gone. Drugs and ablation have no role. Pacemakers or CRT provide what the biology can no longer deliver.
- The mechanism is the map. Identify the mechanism, characterize the substrate, assess the anatomy, and the right therapy follows logically. This framework applies to every arrhythmia in clinical practice.
Quick Reference
Decision Framework
Quick Reference
The Complete Story
Ion channel → tissue → ECG → EP lab → therapy
From cell to cath lab.